Pothiawala Salma, Hsu Mei-Yu, Yang Clarissa, Kesari Santosh, Ibrahimi Omar A
Department of Dermatology and Cutaneous Surgery, University of South Florida College of Medicine, Tampa, FL, USA.
J Drugs Dermatol. 2010 Sep;9(9):1142-4.
Temozolomide is an oral alkylating agent approved for the treatment of glioblastoma and anaplastic astrocytoma, and is currently under clinical investigation for the treatment of brain metastases from a variety of cancers. Temozolomide is well tolerated, and the reported dermatologic side effects of this medication are limited. Here, the authors report the first case of an urticarial hypersensitivity reaction induced by temozolomide. As this drug will likely be increasingly utilized in the near future, it is important to be aware of its potential to cause adverse cutaneous manifestations.
替莫唑胺是一种口服烷化剂，已被批准用于治疗胶质母细胞瘤和间变性星形细胞瘤，目前正在进行临床试验，用于治疗多种癌症的脑转移。替莫唑胺耐受性良好，该药物报告的皮肤副作用有限。在此，作者报告了首例由替莫唑胺引起的荨麻疹超敏反应病例。由于这种药物在不久的将来可能会越来越多地被使用，了解其引起皮肤不良反应的可能性很重要。
